Accusoft today announces that its apps for Apple® Inc.’s iPhone and iPad are compatible with the new operating system for those devices, iOS 7. Both iOS 7-compatible apps--ThinPic and Barcode Scanner--are available through the iTunes App store.

Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that QST Consultations, Ltd. has selected Merge's eClinical OS™ solution as its preferred clinical trial platform to support Phases I, II, and III and Post-Marketing studies on a global basis.

Konica Minolta Medical Imaging announces that the U.S. Food and Drug Administration (FDA) has cleared the Aero DR 10 x 12 wireless plate for sale.  This new plate is an ideal solution for sites seeking a smaller and lighter wireless flat panel for use in general X-ray and in specialty applications where smaller is just the right size, such as orthopedics and pediatrics. This includes the NICU where the Aero DR 10 x 12 detector fits most basinets and can be used with all major portable X-ray systems from various manufacturers. 

The increasing importance and number of radiological images in clinical trials has raised technical and methodological issues for CROs globally. To make trials more efficient and ensure compliance, syneed medidata GmbH, an independent CRO in Germany, has signed a Master Services Agreement with Boston’s AG Mednet.

Increased awareness of the importance of mammography screening and new imaging modalities that can help with early detection are vital tools in the continuing battle against breast cancer, notes Anne Richards, Carestream's Clinical Development Manager for Women's Healthcare.<http://www.carestream.com/womenshealthcare.html>

Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has acquired from Datascope Corp. the SAFEGUARD(R) Pressure Assisted Device, which assists in obtaining and maintaining hemostasis after a femoral procedure, and the AIR-BAND(TM) Radial Compression Device, which is indicated to assist hemostasis of the radial artery puncture site while maintaining visibility.

UltraSPECT, a leading provider of image reconstruction technology that reduces radiopharmaceutical dose and acquisition time for nuclear medicine (NM) exams, announces today that study data has shown UltraSPECT solutions are a viable method for meeting American Society of Nuclear Cardiology (ASNC) low dose guidelines. Furthermore, technologists are able to rely on their existing imaging protocols, providing added confidence in overall results. UltraSPECT will be demonstrating this solution to conference attendees at the upcoming ASNC Annual Meeting, September 26-29, in Chicago.“What this preliminary data shows us is that healthcare facilities do not have to change their standard imaging protocols to meet ASNC guidelines to lower dose,” explained Gordon DePuey, MD, director of Nuclear Medicine at St. Luke’s-Roosevelt Hospital, New York. “I am looking forward to seeing the great progress that the cardiovascular imaging community can make in 2014 as proven and viable solutions are applied to lower the dose for the benefit of patients and to continue to advance healthcare.”

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a €206K firm contract with one of its top 10 biopharmaceutical company client. The contract covers the implementation of an exploratory imaging biomarker, tumor volume, in a first-in-man phase I study on adult patients with advanced malignant solid tumors.  Within the framework of the contract, Progression Free Survival (PFS) will be measured on patients enrolled with RECIST 1.1 1. This widely-used standard criterion for response evaluation in solid tumors is based on lesion axial diameter measurements. In parallel, MEDIAN will implement an exploratory imaging biomarker based on tumor volume that provides more accurate and earlier information regarding patient response to therapy.